Barclays’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-32,400
| Closed | -$186K | – | 5565 |
|
|
2025
Q2 | $186K | Hold |
32,400
| – | – | ﹤0.01% | 4329 |
|
|
2025
Q1 | $264K | Buy |
+32,400
| New | +$300K | ﹤0.01% | 3896 |
|
|
2024
Q3 | – | Sell |
-114,000
| Closed | -$1.13M | – | 5347 |
|
|
2024
Q2 | $1.13M | Buy |
+114,000
| New | +$1.17M | ﹤0.01% | 2529 |
|
|
2021
Q2 | – | Sell |
-300
| Closed | -$3K | – | 4934 |
|
|
2021
Q1 | $3K | Buy |
+300
| New | +$4.64K | ﹤0.01% | 4523 |
|
|
2019
Q3 | – | Sell |
-89,000
| Closed | -$1.11M | – | 6830 |
|
|
2019
Q2 | $1.11M | Buy |
+89,000
| New | +$1.13M | ﹤0.01% | 3574 |
|
|
2018
Q3 | – | Sell |
-8,500
| Closed | -$133K | – | 7212 |
|
|
2018
Q2 | $133K | Buy |
+8,500
| New | +$128K | ﹤0.01% | 5056 |
|
|
2017
Q4 | – | Sell |
-115,400
| Closed | -$1.74M | – | 6972 |
|
|
2017
Q3 | $1.74M | Buy |
+115,400
| New | +$1.53M | ﹤0.01% | 2485 |
|
|
2017
Q1 | – | Sell |
-67,500
| Closed | -$335K | – | 6815 |
|
|
2016
Q4 | $335K | Hold |
67,500
| – | – | ﹤0.01% | 3734 |
|
|
2016
Q3 | $500K | Buy |
+67,500
| New | +$456K | ﹤0.01% | 3222 |
|
Other funds holding FOLD
Barclays's FOLD Position: Q2 2026 in Review
Barclays sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 1,338,482 shares — an estimated $19.4M sold.
Barclays first reported a position in FOLD in Q2 2013 and held it in 51 quarters. The position peaked at $19.4M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Barclays reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Barclays sold 1,338,482 Amicus Therapeutics shares in Q2 2026, an estimated $19.4M.
- Barclays first reported a position in Amicus Therapeutics in Q2 2013 and held it in 51 quarters.
- Barclays's Amicus Therapeutics position peaked at $19.4M in Q1 2026.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.